# Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy

> **NCT03458559** · PHASE3 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 402 (estimated)

## Conditions studied

- Prostate Cancer Metastatic to Bone

## Interventions

- **DRUG:** Radium-223 chloride
- **DRUG:** Rhenium-188-HEDP

## Key facts

- **NCT ID:** NCT03458559
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-16
- **Primary completion:** 2022-05-16
- **Final completion:** 2024-05-16
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03458559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03458559, "Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03458559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*